|Bid||39.74 x 1000|
|Ask||39.80 x 800|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||0.92|
|PE Ratio (TTM)||48.50|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.80|
Developing new automation options for QuantiFERON®-TB Gold Plus – the modern blood-based test for TB detection – and new QFT Access for high burden, low-resource regions
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like QIAGEN N.V. (NYSE:QGEN), with a market cap of US$9.0b, are often out of the spotlight.Read More...
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Non-exclusive collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB de
QIAGEN N.V. announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2018, with the U.S.
Qiagen NV NYSE:QGENView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $541 million. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In December 2018, QIAGEN N.V. (NYSE:QGEN) announced its most recent earnings update, which indicated that the business experienced a major tailwind, more than doubling its earnings from the prior year.Read More...
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
Frankfurt Prime Standard: QIA) today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. (CURE.NX), to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria. QIAGEN has acquired an exclusive license to leverage Ares Genetics’ proprietary antimicrobial resistance database, ARESdb, as well as bioinformatics tools and workflows from the ARES Technology Platform, AREStools, in QIAGEN’s bioinformatics products and services for researchers.
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
This exciting area of cancer research could turn into a huge industry. How can investors potentially profit?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in QIAGEN N.V.Read More...
Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and -1.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Venlo, Netherlands-based company said it had profit of 26 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, came to 40 cents per share. The results met Wall Street ...